Multiple primary cancer, including transitional cell carcinoma of the upper uroepithelial tract in a multigeneration HNPCC family: Molecular genetic, diagnostic, and management implications

American Journal of Gastroenterology

Volumn 98, Issue 3, 2003, Pages 664-670

  Lynch, Henry T ^a   Taylor, Rodney J ^b   Lynch, Jane F ^b   Knezetic, Joseph A ^b   Barrows, Ali ^b   Fodde, Riccardo ^b   Wijnen, Juul ^b   Wagner, Anja ^b  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MSH2;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DECISION MAKING; ENDOMETRIUM CANCER; FAMILIAL CANCER; FAMILY; FAMILY STUDY; FEMALE; GENE IDENTIFICATION; GENE MUTATION; GENE SEGREGATION; GENETIC PROCEDURES; GERM LINE; HUMAN; MALE; MOLECULAR GENETICS; MULTIPLE CANCER; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; SMALL INTESTINE CANCER; TRANSITIONAL CELL CARCINOMA;

EID: 0037343935     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2003.07329.x     Document Type: Article

References (47)

1. Vogelstein B, Kinzler KW. The genetic basis of human cancer. New York: McGraw-Hill, 1998.
2. Lynch HT, Smyrk TC. Classification of familial adenomatous polyposis: A diagnostic nightmare. Am J Hum Genet 1998; 62:1288-9.
3. Lynch HT, de la Chapelle A. Genetic susceptibility to nonpolyposis colorectal cancer. J Med Genet 1999;36:801-18.
4. Herrera L. Familial adenomatous polyposis. New York: Alan R. Liss, 1990.
5. Lynch HT, Smyrk T, Lanspa SJ, et al. Flat adenomas in a colon cancer-prone kindred. J Natl Cancer Inst 1988;80:278-82.
6. Lynch HT, Smyrk TC, Watson P, et al. Hereditary flat adenoma syndrome: A variant of familial adenomatous polyposis? Dis Colon Rectum 1992;35:411-21.
7. Spirio L, Otterud B, Stauffer D, et al. Linkage of a variant or attenuated form of adenomatous polyposis coli to the adenomatous polyposis coli (APC) locus. Am J Hum Genet 1992; 51:92-100.
8. Lynch HT, Smyrk T, McGinn T, et al. Attenuated familial adenomatous polyposis (AFAP): A phenotypically and genotypically distinctive variant of FAP. Cancer 1995;76:2427-33.
9. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42.
10. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
11. Zhang W, Labordé PM, Coombes KR, et al. Cancer genomics: Promises and complexities. Clin Cancer Res 2001;7:2159-67.
12. Balis FM. Evolution of anticancer drug discovery and the role of cell-based screening. J Natl Cancer Inst 2002;94:78-9.
13. Lynch HT, Watson P. AFAP: Variety is the spice of life. Gut 1998;43:451-2.
14. Fusaro RM, Lemon SJ, Lynch HT. The Muir-Torre syndrome. A variant of hereditary nonpolyposis colorectal cancer syndrome. J Tumor Marker Oncol 1996;11:19-31.
15. Lynch PM, Lynch HT, Harris RE. Hereditary proximal colonic cancer. Dis Colon Rectum 1977;20:661-8.
16. Lynch HT, Krush AJ, Larsen AL. Heredity and multiple primary malignant neoplasms: Six cancer families. Am J Med Sci 1967;254:322-9.
17. Watson P, Lynch HT. The tumor spectrum in HNPCC. Anticancer Res 1994;14:1635-40.
18. Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999; 81:214-8.
19. Fusaro RM, Lynch HT, Pester J, et al. Torre's syndrome as phenotypic expression of cancer family syndrome. Arch Dermatol 1980;116:986-7.
20. Lynch HT, Lynch PM, Pester JA, et al. Sebaceous neoplasia and visceral cancer (Torre's syndrome) and its relationship to the cancer family syndrome. In: Lynch HT, Fusaro RM, eds. Cancer-associated genodermatoses. New York: Van Nostrand Reinhold, 1982:366-93.
21. Lynch HT, Fusaro RM, Roberts L, et al. Muir-Torre syndrome in several members of a family with a variant of the cancer family syndrome. Br J Dermatol 1985;113:295-301.
22. Lynch HT, Fusaro RM. Muir-Torre syndrome: Heterogeneity, natural history, diagnosis, and management. Prob Gen Surg 1993;10:1-14.
23. Lynch HT, Leibowitz R, Smyrk T, et al. Colorectal cancer and the Muir-Torre syndrome in a Gypsy family: A review. Am J Gastroenterol 1999;94:575-80.
24. Peltomäki P, Aaltonen L, Sistonen P, et al. Genetic mapping of a locus predisposing to human colorectal cancer. Science 1993;260:810-2.
25. Lynch HT. Family Information Service and hereditary cancer. Cancer 2001;91:625-8.
26. Wijnen JT, Vasen HFA, Khan PM, et al. Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. N Engl J Med 1998;339:511-8.
27. Wijnen J, de Leeuw W, Vasen H, et al. Familial endometrial cancer in female carriers of MSH6 germline mutations. Nat Genet 1999;23:142-4.
28. Fodde R, Losekoot M, Casula L, et al. Nucleotide sequence of the Belgian G gamma+(A gamma delta beta)0-thalassemia deletion breakpoint suggests a common mechanism for a number of such recombination events. Genomics 1990;8:732-5.
29. Yan H, Papadopoulos N, Marra G, et al. Conversion of diploidy to haploidy: Individuals susceptible to multigene disorders may now be spotted more easily. Nature 2000;403:723-4.
30. Papadopoulos N, Leach FS, Kinzler KW, et al. Monoallelic mutation analysis for identifying germline mutations. Nat Genet 1995;11:100-2.
31. Wagner A, Klift H, Franken P, et al. A 10 Mb paracentric inversion of chromosome 2p inactivates MSH2 and is responsible for HNPCC in a North American kindred. Genes Chromosomes Cancer 2002;35:49-57.
32. Vasen HFA, Mecklin J-P, Meera Khan P, et al. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991;34: 424-425
33. Vasen HFA, Watson P, Mecklin J-P, et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC. Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology 1999;116: 1453-6.
34. Lindor NM, Burgart LJ, Leontovich O, et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 2002;20:1043-8.
35. de la Chapelle A. Microsatellite instability phenotype of tumors: Genotyping or immunohistochemistry? The jury is still out. J Clin Oncol 2002;20:897-9.
36. Nicolaides NC, Papadopoulos N, Liu B, et al. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 1994;371:75-80.
37. Bronner CE, Baker SM, Morrison PT, et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary nonpolyposis colon cancer. Nature 1994;368:258-6.
38. Fishel R, Lescoe MK, Rao MRS, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993;75:1027-8.
39. Akiyama Y, Sato H, Yamada T, et al. Germ-line mutation of the hMSH6/GTBP gene in an atypical hereditary nonpolyposis colorectal cancer kindred. Cancer Res 1997;57:3920-3.
40. Miyaki M, Konishi M, Tanaka K, et al. Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nat Genet 1997;17:271-2.
41. Wu Y, Berends MJW, Sijmons RH, et al. A role for MLH3 in hereditary nonpolyposis colorectal cancer. Nat Genet 2001; 29:137-8.
42. Lipkin SM, Wang V, Jacoby R, et al. MLH3: A DNA mismatch repair gene associated with mammalian microsatellite instability. Nat Genet 2000;24:27-34.
43. Peltomäki P, Vasen HFA, International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Mutations predisposing to hereditary nonpolyposis colorectal cancer: Database and results of a collaborative study. Gastroenterology 1997;113:1146-58.
44. Nicolaides NC, Littman SJ, Modrich P, et al. A naturally occurring hPMS2 mutation can confer a dominant negative mutator phenotype. Mol Cell Biol 1998;18:1635-41.
45. Vasen HFA, Stormorken A, Menko FH, et al. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: A study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol 2001;19:4074-80.
46. Järvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000; 118:829-34.
47. Watson P, Vasen HFA, Mecklin J-P, et al. The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer. Am J Med 1994;96:516-20.